PTPI Live signals | Maximize Profits with Getagraph.com

SELL 159184 min ago

@ $1.580

Issued: 13 Feb 2024 @ 13:18

Return: -61.13%

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Stats
Today's Volume	57 441.00
Average Volume	499 233
Market Cap	4.30M
EPS	$0 ( 2024-05-20 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0800
ATR14	$0.00900 (1.42%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-21	Bernstein Bruce	Buy	40 000	Stock Option (Right to Buy)
2023-12-21	Boctor Fady	Buy	54 533	Stock Option (Right to Buy)
2023-12-21	Boctor Fady	Buy	49 645	Common Stock
2023-12-21	Walker Wayne Remell	Buy	40 000	Stock Option (Right to Buy)
2023-12-21	Arnold Mitchell	Buy	20 000	Stock Option (Right to Buy)

INSIDER POWER
90.87
Last 73 transactions
Buy: 12 778 148 \| Sell: 66 349

Volume Correlation

Long: -0.03 (neutral)

Short: 0.72 (moderate)

Signal:(68.492) Neutral

Petros Pharmaceuticals, Correlation

10 Most Positive Correlations
BRZE	0.894
IDXX	0.885
GDYN	0.885
EZGO	0.883
NCNA	0.88
ATER	0.88
GSHD	0.879
ASUR	0.879
SHLS	0.879
CTSH	0.877

10 Most Negative Correlations
LWAY	-0.926
CENX	-0.903
CURI	-0.892
SOHU	-0.884
VFF	-0.882
AMRK	-0.881
LABP	-0.878
QRHC	-0.878
NN	-0.877
SMTC	-0.875

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Petros Pharmaceuticals, Correlation - Currency/Commodity

-0.04
( neutral )

0.20
( neutral )

0.00
( neutral )

0.10
( neutral )

0.03
( neutral )

Petros Pharmaceuticals, Financials

Annual	2023
Revenue:	$5.82M
Gross Profit:	$908 201 (15.60 %)
EPS:	$-3.75

FY	2023
Revenue:	$5.82M
Gross Profit:	$908 201 (15.60 %)
EPS:	$-3.75

FY	2022
Revenue:	$5.99M
Gross Profit:	$3.70M (61.79 %)
EPS:	$-13.06

FY	2021
Revenue:	$7.81M
Gross Profit:	$6.21M (79.52 %)
EPS:	$-1 682.68

Financial Reports:

No articles found.

Petros Pharmaceuticals, Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Petros Pharmaceuticals,

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.